Browse CD55

Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Lipid-anchor, GPI-anchor.; SUBCELLULAR LOCATION: Isoform 3: Secreted ; SUBCELLULAR LOCATION: Isoform 4: Secreted ; SUBCELLULAR LOCATION: Isoform 5: Secreted ; SUBCELLULAR LOCATION: Isoform 6: Cell membrane Lipid-anchor, GPI-anchor ; SUBCELLULAR LOCATION: Isoform 7: Cell membrane Lipid-anchor, GPI-anchor
Domain PF00084 Sushi repeat (SCR repeat)
Function

This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829). ; FUNCTION: (Microbial infection) Acts as a receptor for Coxsackievirus A21, coxsackieviruses B1, B3 and B5. ; FUNCTION: (Microbial infection) Acts as a receptor for Human enterovirus 70 and D68 (Probable). ; FUNCTION: (Microbial infection) Acts as a receptor for Human echoviruses 6, 7, 11, 12, 20 and 21.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002367 cytokine production involved in immune response
GO:0002369 T cell cytokine production
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002455 humoral immune response mediated by circulating immunoglobulin
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002831 regulation of response to biotic stimulus
GO:0002920 regulation of humoral immune response
GO:0002921 negative regulation of humoral immune response
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006956 complement activation
GO:0006958 complement activation, classical pathway
GO:0006959 humoral immune response
GO:0007159 leukocyte cell-cell adhesion
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0010955 negative regulation of protein processing
GO:0016064 immunoglobulin mediated immune response
GO:0016485 protein processing
GO:0019058 viral life cycle
GO:0019724 B cell mediated immunity
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030260 entry into host cell
GO:0030449 regulation of complement activation
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0031664 regulation of lipopolysaccharide-mediated signaling pathway
GO:0032496 response to lipopolysaccharide
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035739 CD4-positive, alpha-beta T cell proliferation
GO:0035743 CD4-positive, alpha-beta T cell cytokine production
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0043900 regulation of multi-organism process
GO:0044409 entry into host
GO:0045730 respiratory burst
GO:0045785 positive regulation of cell adhesion
GO:0045861 negative regulation of proteolysis
GO:0045916 negative regulation of complement activation
GO:0046631 alpha-beta T cell activation
GO:0046633 alpha-beta T cell proliferation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046640 regulation of alpha-beta T cell proliferation
GO:0046641 positive regulation of alpha-beta T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0046718 viral entry into host cell
GO:0048193 Golgi vesicle transport
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050727 regulation of inflammatory response
GO:0050777 negative regulation of immune response
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051604 protein maturation
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0055074 calcium ion homeostasis
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070613 regulation of protein processing
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071593 lymphocyte aggregation
GO:0072376 protein activation cascade
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903317 regulation of protein maturation
GO:1903318 negative regulation of protein maturation
GO:2000257 regulation of protein activation cascade
GO:2000258 negative regulation of protein activation cascade
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation
GO:2000561 regulation of CD4-positive, alpha-beta T cell proliferation
GO:2000563 positive regulation of CD4-positive, alpha-beta T cell proliferation
Molecular Function GO:0001618 virus receptor activity
Cellular Component GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0030133 transport vesicle
GO:0031225 anchored component of membrane
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-6807878: COPI-mediated anterograde transport
R-HSA-373080: Class B/2 (Secretin family receptors)
R-HSA-166658: Complement cascade
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-597592: Post-translational protein modification
R-HSA-977606: Regulation of Complement cascade
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD55 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD55 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22531721Endometrial Serous AdenocarcinomaInhibit immunityDownregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
23474221Breast Carcinoma; Lung Carcinoma; Ovarian CarcinomaInhibit immunity (T cell function); essential for immunotherapyThe therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement-mediated attack, primarily through the over-expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Delivery of chemically stabilized anti-mCRP siRNAs using cationic lipoplexes, AtuPLEXes, to HER2-over-expressing BT474, SK-BR-3 (breast), SKOV3 (ovarian) and Calu-3 (lung) cancer cells reduced mCRPs expression by 85-95%.
24973443colorectal carcinomaInhibit immunityRNA interference-induced knockdown or overexpression of membrane-bound complement regulatory proteins revealed CD55 expression to be a pivotal determinant of anti-EGFR-IgG3-triggered CML and to force a switch from classical complement pathway activation to C1q-dependent alternative pathway amplification.
24903480Burkitt lymphomaInhibit immunityWe developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to enhance C-mediated functions.
17671212Ovarian CarcinomaResistant to immunotherapyCombined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Blockade of CD55 in vitro led to enhanced deposition of C activation product C3b and increased cytotoxicity mediated by beta-glucan-primed neutrophils. We conclude that CD55 suppresses tumor killing by antitumor mAb plus beta-glucan therapy (and, perhaps, in other circumstances).
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD55 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD55 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0080.981
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5670.824
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3920.823
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2670.446
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4150.841
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0760.978
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2070.689
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3540.852
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.80.709
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9010.537
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3970.523
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0180.893
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD55 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD55. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD55. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD55.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD55. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD55 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD55 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD55
NameCD55 molecule, decay accelerating factor for complement (Cromer blood group)
Aliases CROM; DAF; decay accelerating factor for complement (CD55, Cromer blood group system); CD55 antigen; CD anti ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD55 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD55.
ID Name Drug Type Targets #Targets
DB00446ChloramphenicolSmall MoleculeCD551